Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.1020793
Keywords
case report; nab-paclitaxel; PD-1; metastatic bladder cancer; sintilimab
Categories
Funding
- Zhejiang Natural Science Fund
- Ningbo Social Development Fund [LY20H050002]
- Fund of Ningbo Clinical Research Center for Urological Disease [202002N3192]
- [2019A21001]
Ask authors/readers for more resources
This article described a successful case of using nab-paclitaxel plus sintilimab to treat metastatic bladder cancer (mBC). After nine cycles of therapy, complete remission (CR) was achieved without severe side effects during the treatment.
This article described a patient with metastatic bladder cancer (mBC) who was successfully treated with nab-paclitaxel plus sintilimab. Localized muscle-invasive bladder cancer (MIBC) was discovered in a 56-year-old man who received radical cystectomy and platinum-based adjuvant chemotherapy. Eleven months after cystectomy, this patient developed numerous hepatic and pelvic metastases and progressed to mBC. The patient was given an anti-PD-1 antibody (sintilimab 200mg, q3w) in combination with Nab-paclitaxel (100mg, qw) for mBC. Complete remission (CR) was achieved after nine cycles of therapy, and the patient had no severe side effects during the treatment. The disease remained in CR after 41 months of follow-up. This case suggests that nab-paclitaxel combined with sintilimab is a safe and effective option in treatment of mBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available